Cervical Cancer Screening
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB002 alerts
Get alerted when Policy CPCPLAB002 changes without checking for updates manually.
Monitor payer policy activity
Defines reimbursement and coding criteria for cervical cancer screening tests (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix, including age- and risk-based frequencies and excluded scenarios, for BCBSOK products.
Screening recommendations were revised to allow immunocompromised individuals of all ages to follow age-specific frequency rules and to reorganize high-risk over-65 guidance.
Added an explicit statement that cervical cancer screening for individuals less than 21 years of age is not reimbursable for situations not otherwise addressed.
Removed prior eligibility language that allowed screening for individuals under 21 only when specific high-risk conditions were present (HIV, immunocompromise, prior cancer/dysplasia, transplant).
Medically Necessary and Excluded Screening Criteria
Medically necessary coverage criteria
Covered when the following age- and risk-based criteria are met
applies to individuals with a cervix
Pap cytology preferred; HPV testing not primary
choose one of the listed modalities and intervals
see definition of high-risk
genotyping for HPV-16/18 allowed
annual frequency limited to listed conditions
For situations not explicitly addressed in the medically necessary criteria, cervical cancer screening (cervical cytology and/or high-risk HPV testing) for individuals less than 21 years of age is not reimbursable. This exclusion applies to routine screening unless the individual meets one of the specific covered high-risk or clinical indications described elsewhere in this policy (for example, immunosuppression or other conditions that alter screening frequency).
An adequate screening history for purposes of stopping routine cervical cancer screening in individuals over 65 is defined as either: (a) three consecutive negative Pap smears, or (b) two consecutive negative HPV tests within the prior 10 years with the most recent test within 5 years. When an individual over 65 who is not considered high-risk has this adequate screening history, routine screening is not reimbursable. Conversely, individuals over 65 who are considered high-risk remain eligible for screening per the frequency described for ages 30–65.
Procedure and Laboratory Codes
Billing, Documentation, and Provider Responsibilities
Required documentation
Providers are responsible for submission of accurate documentation of services performed. Providers must submit claims using valid HIPAA-approved code sets and follow industry-standard coding guidelines (e.g., UB, AMA CPT, HCPCS, ICD-10-CM/PCS, NDC, DRG, CMS NCCI). Claims are subject to code edit protocols and review against benefit coverage, provider contract terms, medical and payment/coding policies, and claim-adjudication logic. Upon request, providers should supply additional records to support medical necessity and claim details.
- Submit claims with appropriate, HIPAA-compliant code combinations (CPT, HCPCS, ICD-10).
- Maintain and provide clinical documentation to support services and medical necessity when requested.
- Claims may be audited and adjusted per code edits, contract terms, and policy rules.
Procedure codes and reimbursement considerations
The following procedure codes are included for reference; inclusion does not guarantee coverage or reimbursement. Billers should verify member eligibility, applicable frequency rules, and reimbursement criteria before submission. Reimbursement considerations (frequency limits, age-based rules, immunosuppressed/high-risk exceptions) in the policy apply when adjudicating these codes.
- Codes listed are not exhaustive and may be subject to edits or bundling rules.
- Verify member-specific coverage rules (age, risk status, prior screens) before billing.
- Frequency and medical-necessity rules in the Reimbursement Information section govern payment.
Denial triggers
Denials may result from improper coding, noncompliance with HIPAA code set requirements, services falling outside reimbursable age ranges or frequency limits (e.g., routine screening <21 years or >65 years without high-risk criteria), lack of medical necessity, or failure to provide requested documentation. Providers should follow coding guidance and the policy's reimbursement criteria to minimize denial risk.
- Denial triggers: invalid or non-HIPAA code combinations, coding edits, or bundling conflicts.
- Denial triggers: service billed outside allowed age or frequency (routine screening <21; routine screening >65 without high-risk/adequate history).
- Denial triggers: missing or insufficient documentation to support medical necessity or eligibility.
Clinical Background and Rationale
Cervical cancer screening reduces the risk of invasive disease by detecting precancerous lesions early, and major professional organizations and evidence-based guidance inform the reimbursement and interval recommendations adopted in this policy. The policy distinguishes average-risk from high-risk individuals (for example, immunocompromised persons, those with prior high-grade precancerous lesions or cervical cancer, or in-utero DES exposure) and aligns test modality and frequency to age and risk to optimize benefit while avoiding unnecessary testing.
Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.